Observational study in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 3 institutions in 1 country.
Gaetano CicchittoCOVID-19 Hospital "M. Scarlato", Department of Pneumology, 84018 Salerno, Italy.
Lorena CardilloIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.ORCID 0000-0003-3050-1095
Davide SequinoDepartment of Clinical Medicine and Surgery, Section of Respiratory Disease Federico II University Hospital, 80055 Naples, Italy.ORCID 0000-0002-8718-5989
Paola SabatiniUmberto I" Hospital, Unit of Virology and Microbiology, Nocera Inferiore, 84018 Salerno, Italy.
Luisa AdamoUmberto I" Hospital, Unit of Virology and Microbiology, Nocera Inferiore, 84018 Salerno, Italy.
Rosita MarchitielloCOVID-19 Hospital "M. Scarlato", Unit of Clinical Pathology Laboratory, 84018 Salerno, Italy.
Maurizio ViscardiIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.
Loredana CozzolinoIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.
Antonietta CavalleraCOVID-19 Hospital "M. Scarlato", Department of Radiology, 84018 Salerno, Italy.
Marialuisa BocchinoDepartment of Clinical Medicine and Surgery, Section of Respiratory Disease Federico II University Hospital, 80055 Naples, Italy.
Alessandro Sanduzzi ZamparelliDepartment of Clinical Medicine and Surgery, Section of Respiratory Disease Federico II University Hospital, 80055 Naples, Italy.ORCID 0000-0002-0977-2643
Francesco FerrignoCOVID-19 Hospital "M. Scarlato", Department of Pneumology, 84018 Salerno, Italy.
Esterina de CarloIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.ORCID 0000-0001-7883-1283
Claudio de MartinisIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.ORCID 0000-0002-0948-5513
Giovanna FuscoIstituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.ORCID 0000-0003-3139-7672
Istituto Zooprofilattico Sperimentale del Mezzogiorno · ITFederico II University Hospital · ITPoliclinico Umberto I · IT
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Neutralizing monoclonal antibodies (mAbs) for pre- and post-exposure prophylaxis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are largely used to prevent the progression of the disease by blocking viral attachment, host cell entry, and infectivity. Sotrovimab, like other available mAbs, has been developed against the receptor binding Domain of the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series. · full record | OpenQuestion